In consultation: Guidance and quality standards
Showing 1 to 10 of 16
| Title | Consultation | Type | Consultation end date |
|---|---|---|---|
| Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Anitocabtagene autoleucel for treating relapsed or refractory multiple myeloma ID6549 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Sonrotoclax for treating relapsed or refractory mantle cell lymphoma after an anti-CD20 treatment and a BTK inhibitor [ID6654] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma [ID6437] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Extravascular implantable cardioverter defibrillator insertion for preventing sudden cardiac death | Draft scope consultation | Interventional procedures guidance | |
| Norucholic acid for treating primary sclerosing cholangitis [ID6583] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance | |
| Pegcetacoplan for treating complement 3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis in people 12 years and over [ID6489] | Draft guidance | Technology appraisal guidance | |
| Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232] | Draft guidance | Technology appraisal guidance | |
| Bepirovirsen for treating chronic hepatitis B [ID6608] | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators | Technology appraisal guidance |